We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

4 hedge funds and large institutions have $403K invested in Loncar China BioPharma ETF in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more funds holding

Funds holding: 2 → 4 (+2)

28% more capital invested

Capital invested by funds: $314K → $403K (+$89K)

Holders
4
Holders Change
+2
Holders Change %
+100%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$361K
2
AG
Advisor Group
Arizona
+$11.2K
3
TRCT
Tower Research Capital (TRC)
New York
+$983

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$270K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$347K +$361K +16,162 New
Morgan Stanley
2
Morgan Stanley
New York
$44K – – –
AG
3
Advisor Group
Arizona
$11K +$11.2K +500 New
TRCT
4
Tower Research Capital (TRC)
New York
$1K +$983 +44 New
Jane Street
5
Jane Street
New York
– -$270K -12,166 Closed

CHNA Hedge Fund Activity: Q3 2019 in Review

4 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2019, worth a combined $403K — up 28% from $314K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CHNA positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $361K. The largest seller was Jane Street, exiting entirely with an estimated $270K sold.

  • 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q3 2019, up from 2 in Q2 2019.
  • Funds reported $403K of Loncar China BioPharma ETF stock for Q3 2019, up 28% quarter-over-quarter.
  • 3 funds opened new Loncar China BioPharma ETF positions in Q3 2019 and 1 closed out, a net change of +2 holders.
  • The largest Loncar China BioPharma ETF buyer in Q3 2019 was Citadel Advisors, an estimated $361K added.
  • The largest Loncar China BioPharma ETF seller in Q3 2019 was Jane Street, an estimated $270K sold.

Based on aggregated 13F filings for Q3 2019.